China, in December 2019. 1 As of March 20, 2020, 244 602 patients have tested positive
worldwide; and 10 031 (4.1%) of these patients were reported to be deceased because of …

Abstract Background Coronavirus disease 2019 (Covid-19) may disproportionately affect
people with cardiovascular disease. Concern has been aroused regarding a potential …

According to available clinical data,≈ 15% to 30% of the COVID-19 patients are with
hypertension and≈ 2.5% to 15% are with coronary heart disease. 3–5 …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has already surpassed the combined mortality …

The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II
receptor blockers (ARBs) on COVID-19 disease severity have generated considerable …

Coronavirus disease 2019 (COVID-19) is a current pandemic infection caused by a positive-
sense RNA virus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Introduction and objectives Coronavirus disease (COVID-19) has been designated a global
pandemic by the World Health Organization. It is unclear whether previous treatment with …

Importance Data are lacking whether patients with hypertension who are taking angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have …

From the emerging literature, cardiovascular disease appears to play a prominent role in the
COVID-19 pandemic on multiple levels:(i) patients with cardiovascular risk factors and pre …

Aims: We sought to evaluate the association of angiotensin-converting-enzyme inhibitors
(ACEI) or AT1 blockers (ARB) therapy with clinical outcomes in patients with coronavirus …